Design, synthesis, and evaluation of inhibitors of InhA to prevent cell wall biosynthesis in Mycobacterium bovis

Tuberculosis is a disease primarily affecting the lungs caused by Mycobacterium bovis (Mycobacterium tuberculosis in humans) which is transmitted via airborne droplets through mucosal fluids. It is classified as both a major health threat and cattle farming threat as well as a leading cause of death...

Full description

Bibliographic Details
Main Author: Stevenson, Matthew
Format: Thesis (University of Nottingham only)
Language:English
Published: 2020
Subjects:
Online Access:https://eprints.nottingham.ac.uk/60010/
_version_ 1848799710590009344
author Stevenson, Matthew
author_facet Stevenson, Matthew
author_sort Stevenson, Matthew
building Nottingham Research Data Repository
collection Online Access
description Tuberculosis is a disease primarily affecting the lungs caused by Mycobacterium bovis (Mycobacterium tuberculosis in humans) which is transmitted via airborne droplets through mucosal fluids. It is classified as both a major health threat and cattle farming threat as well as a leading cause of death worldwide ranked alongside HIV and in 2016, 1.6 million people died as a result of the disease. It is a particular problem in the farming industry where culling of livestock is generally utilised rather than expensive and lengthy treatment. Most recent statistics from the UK indicated 4,395 new contaminated herds with over 44,000 animals slaughtered due to the disease. The nature of treatment (long-term combination therapy) as well as unwillingness to vaccinate cattle breeds resistance, the subject of which is a growing issue with both multidrug (MDR-TB) and extensively drug resistant (XDR-TB) tuberculosis strains becoming increasingly prevalent worldwide. Isoniazid (INH) is a prodrug activated by KatG, the active form then inhibits InhA. INH is one of the most potent antitubercular drugs which acts to prevent the production and replenishment of mycolic acids, which form the outer coat of the Mycobacterium, by inhibiting the FASII section of the fatty acid biosynthetic pathway. Mutation in KatG renders the prodrug inert but by targeting InhA directly we can still inhibit production of mycolic acids, and as InhA has an identical structure in bovis as in tuberculosis there is the potential for treating both humans and cattle. Work has been carried out on the synthesis of a new class of potential inhibitors based on L-ascorbic acid, which as a readily available starting material that shows little to no toxicity in the body provides an interesting route for drug development. These compounds are considered a second generation of inhibitors compared to the work of Manjunatha et al who screened the Novartis compound library and found 4-hydroxy-2-pyridones had potent antitubercular activity against InhA. A series of compounds have been synthesised incorporating phenyl and benzyl ethers attached to the L-ascorbic acid scaffold. These have been tested in an isolated enzyme assay, with trans-2-octenoyl CoA as substrate, to determine their percentage inhibition of InhA at 50 μM. None of the compounds tested exhibited an inhibitory effect on InhA at this concentration.
first_indexed 2025-11-14T20:40:00Z
format Thesis (University of Nottingham only)
id nottingham-60010
institution University of Nottingham Malaysia Campus
institution_category Local University
language English
last_indexed 2025-11-14T20:40:00Z
publishDate 2020
recordtype eprints
repository_type Digital Repository
spelling nottingham-600102025-02-28T14:49:08Z https://eprints.nottingham.ac.uk/60010/ Design, synthesis, and evaluation of inhibitors of InhA to prevent cell wall biosynthesis in Mycobacterium bovis Stevenson, Matthew Tuberculosis is a disease primarily affecting the lungs caused by Mycobacterium bovis (Mycobacterium tuberculosis in humans) which is transmitted via airborne droplets through mucosal fluids. It is classified as both a major health threat and cattle farming threat as well as a leading cause of death worldwide ranked alongside HIV and in 2016, 1.6 million people died as a result of the disease. It is a particular problem in the farming industry where culling of livestock is generally utilised rather than expensive and lengthy treatment. Most recent statistics from the UK indicated 4,395 new contaminated herds with over 44,000 animals slaughtered due to the disease. The nature of treatment (long-term combination therapy) as well as unwillingness to vaccinate cattle breeds resistance, the subject of which is a growing issue with both multidrug (MDR-TB) and extensively drug resistant (XDR-TB) tuberculosis strains becoming increasingly prevalent worldwide. Isoniazid (INH) is a prodrug activated by KatG, the active form then inhibits InhA. INH is one of the most potent antitubercular drugs which acts to prevent the production and replenishment of mycolic acids, which form the outer coat of the Mycobacterium, by inhibiting the FASII section of the fatty acid biosynthetic pathway. Mutation in KatG renders the prodrug inert but by targeting InhA directly we can still inhibit production of mycolic acids, and as InhA has an identical structure in bovis as in tuberculosis there is the potential for treating both humans and cattle. Work has been carried out on the synthesis of a new class of potential inhibitors based on L-ascorbic acid, which as a readily available starting material that shows little to no toxicity in the body provides an interesting route for drug development. These compounds are considered a second generation of inhibitors compared to the work of Manjunatha et al who screened the Novartis compound library and found 4-hydroxy-2-pyridones had potent antitubercular activity against InhA. A series of compounds have been synthesised incorporating phenyl and benzyl ethers attached to the L-ascorbic acid scaffold. These have been tested in an isolated enzyme assay, with trans-2-octenoyl CoA as substrate, to determine their percentage inhibition of InhA at 50 μM. None of the compounds tested exhibited an inhibitory effect on InhA at this concentration. 2020-07-24 Thesis (University of Nottingham only) NonPeerReviewed application/pdf en arr https://eprints.nottingham.ac.uk/60010/1/Thesis%20Submission%20Matthew%20Stevenson.pdf Stevenson, Matthew (2020) Design, synthesis, and evaluation of inhibitors of InhA to prevent cell wall biosynthesis in Mycobacterium bovis. PhD thesis, University of Nottingham. Medicinal Chemistry Biological Chemistry Assay Tuberculosis InhA Assay Tuberculosis InhA Mycobacterium bovis
spellingShingle Medicinal Chemistry
Biological Chemistry
Assay
Tuberculosis
InhA
Assay
Tuberculosis
InhA
Mycobacterium bovis
Stevenson, Matthew
Design, synthesis, and evaluation of inhibitors of InhA to prevent cell wall biosynthesis in Mycobacterium bovis
title Design, synthesis, and evaluation of inhibitors of InhA to prevent cell wall biosynthesis in Mycobacterium bovis
title_full Design, synthesis, and evaluation of inhibitors of InhA to prevent cell wall biosynthesis in Mycobacterium bovis
title_fullStr Design, synthesis, and evaluation of inhibitors of InhA to prevent cell wall biosynthesis in Mycobacterium bovis
title_full_unstemmed Design, synthesis, and evaluation of inhibitors of InhA to prevent cell wall biosynthesis in Mycobacterium bovis
title_short Design, synthesis, and evaluation of inhibitors of InhA to prevent cell wall biosynthesis in Mycobacterium bovis
title_sort design, synthesis, and evaluation of inhibitors of inha to prevent cell wall biosynthesis in mycobacterium bovis
topic Medicinal Chemistry
Biological Chemistry
Assay
Tuberculosis
InhA
Assay
Tuberculosis
InhA
Mycobacterium bovis
url https://eprints.nottingham.ac.uk/60010/